Publications by authors named "Kento Kaminogo"
Medication-related osteonecrosis of the jaw is a serious disease occurring in patients with cancer and osteoporosis, who are undergoing treatment with antiresorptive agents (ARAs) such as bisphosphonate (BP) or denosumab, an antibody targeting receptor activator of NF-κB ligand. Recently, stem cell-based therapy has been shown to be effective in preventing the development of bisphosphonate-related osteonecrosis of the jaw. However, studies on denosumab-related osteonecrosis of the jaw (DRONJ) remain limited.
View Article and Find Full Text PDFArticle Synopsis
- Chemotherapy-induced alopecia (CIA) affects about 65% of patients undergoing chemotherapy like cyclophosphamide, and there are limited treatment options available.
- Human dental pulp stem cells (DPSCs) release growth-promoting factors, and their conditioned medium (DPSC-CM) can enhance hair growth, especially when cultured under low-oxygen (hypoxic) conditions.
- Research showed that DPSC-CM reduces cell death in keratinocytes affected by cyclophosphamide and promotes hair regrowth in mice, indicating its potential as a safe treatment for CIA.